In the realm of healthcare, neurology is experiencing a revival, marked by notable clinical advancements, increased deal activity, and a resurgence of interest from pharmaceutical giants. While perhaps not as widely discussed as topics like obesity, neuroscience’s return to the spotlight is evident through various indicators, including rising deal numbers and significant mergers and acquisitions. To set the scene, three major mergers and acquisitions in 2023 highlighted Big Pharma’s renewed focus on neurology. Bristol Myers Squibb’s acquisition of Karuna Therapeutics for $14 billion, AbbVie’s $8.7 billion deal for Cerevel, and Biogen’s $7.3 billion purchase of Reata (gaining rare disease drug Skyclarys for a rare neurological disorder), demonstrate the potential for substantial returns in the neurology market.
Read the full article: Neurology’s Renewal for Pharma Companies //
Source: https://www.evaluate.com/blog/neurologys-renewal/